Join the "Treating NSCLC with Ramucirumab" Session

Dear Dr. Renukaprasad A R, Ramucirumab is a successful second-line treatment option for patients with stage IV non-small cell lung cancer. These results from the REVEL study appear to be promising for managing the advanced stages of NSCLC. Join us TODAY from 07:30 PM to 08:30 PM IST to get deeper insights into the role of ramucirumab! We look forward to your active participation in this information-packed discussion! Highlights: Welcome and introduction Optimal management in EGFR-M+ NSCLC (Relaying RELAY + clinical case discussion) by Dr. Ashish Kaushal 2nd line NSCLC landscape updates for Cyramza® (REVEL + clinical case discussion) by Dr. Ghanashyam Biswas Summary and key takeaways Join the Session Docplexus is one of the world's largest online communities Pune - 411045, India info@docplexus.co.in�� |� +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*